DeepMed Research

ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Post Approval Study of the AcrySof® IQ Toric Intraocular Lens (IOL) Models SN6AT6-SN6AT9

Completed

Conditions: Astigmatism
Cataracts

Interventions: Device: SN60WF Intraocular Lens
Device: SN6AT6 Intraocular Lens
Device: SN6AT7 Intraocular Lens
Device: SN6AT8 Intraocular Lens
Device: SN6AT9 Intraocular Lens

First Posted Date: 2012-05-18

Last Posted Date: 2015-08-04

Lead Sponsor: Alcon Research

Target Recruit Count: 477

Registration Number: NCT01601665

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: ReNu MultiPlus® contact lens solution
Device: AOSEPT® Plus contact lens solution
Device: Etafilcon A contact lenses
Device: Lotrafilcon B contact lenses
Device: COMPLETE® MPS Easy Rub® Formula contact lens solution

First Posted Date: 2012-05-09

Last Posted Date: 2014-07-25

Lead Sponsor: Alcon Research

Target Recruit Count: 100

Registration Number: NCT01594294

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Moxifloxacin ophthalmic solution, 0.5%
Drug: Ofloxacin ophthalmic solution, 0.3%

First Posted Date: 2012-04-10

Last Posted Date: 2015-05-12

Lead Sponsor: Alcon Research

Target Recruit Count: 985

Registration Number: NCT01573910

Locations: 🇨🇳
Alcon (China) Ophthalmic Product Co., Ltd., Beijing, China

Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Delefilcon A contact lenses
Device: Narafilcon A contact lenses

First Posted Date: 2012-03-23

Last Posted Date: 2014-01-07

Lead Sponsor: Alcon Research

Target Recruit Count: 123

Registration Number: NCT01561560

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

Pre-Lens Tear Film Performance of Silicone Hydrogel Daily Disposable Contact Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Delefilcon A contact lens
Device: Narafilcon A contact lens
Device: Filcon II 3 contact lens

First Posted Date: 2012-03-08

Last Posted Date: 2013-06-24

Lead Sponsor: Alcon Research

Target Recruit Count: 39

Registration Number: NCT01548833

Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa

Phase 3

Completed

Conditions: Acute Otitis Externa

Interventions: Other: AL-60371 Vehicle
Drug: AL-60371, 0.3% Otic Suspension

First Posted Date: 2012-02-20

Last Posted Date: 2014-07-08

Lead Sponsor: Alcon Research

Target Recruit Count: 768

Registration Number: NCT01535599

Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa

Phase 3

Completed

Conditions: Acute Otitis Externa

Interventions: Drug: AL-60371, 0.3% otic suspension
Drug: AL-60371 Vehicle

First Posted Date: 2012-02-17

Last Posted Date: 2013-12-10

Lead Sponsor: Alcon Research

Target Recruit Count: 589

Registration Number: NCT01535560

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Brinzolamide/timolol maleate fixed combination

First Posted Date: 2012-01-25

Last Posted Date: 2015-08-07

Lead Sponsor: Alcon Research

Target Recruit Count: 50

Registration Number: NCT01518244

VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery

Phase 3

Withdrawn

Conditions: Cataracts

Interventions: Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)

First Posted Date: 2012-01-24

Last Posted Date: 2014-03-26

Lead Sponsor: Alcon Research

Registration Number: NCT01515826

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Phase 4

Terminated

Conditions: Glaucoma

Interventions: Drug: Brinzolamide/timolol maleate fixed combination

First Posted Date: 2012-01-23

Last Posted Date: 2013-10-21

Lead Sponsor: Alcon Research

Target Recruit Count: 9

Registration Number: NCT01514734

Locations: 🇧🇷
Contact Alcon Call Center for Trial Locations, São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy